Last reviewed · How we verify
SHR-1314
SHR-1314 is a small molecule targeting the CD47/SIRPα axis.
SHR-1314 is a small molecule targeting the CD47/SIRPα axis. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | SHR-1314 |
|---|---|
| Also known as | Placebo |
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | CD47/SIRPα inhibitor |
| Target | CD47/SIRPα axis |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
SHR-1314 works by blocking the interaction between CD47 and SIRPα, which is involved in tumor immune evasion. This blockade leads to the activation of immune cells and the elimination of cancer cells.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Anemia
- Thrombocytopenia
- Neutropenia
Key clinical trials
- A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis (PHASE3)
- The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis (PHASE3)
- Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients (PHASE2)
- Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis (PHASE2)
- A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis (PHASE3)
- A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices (PHASE1)
- Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis (PHASE2, PHASE3)
- Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |